醫(yī)學(xué)論文范文:不同劑量阿托伐他汀對肺心病患者big�睧T及hs�睠RP及PAP水平的影響

醫(yī)學(xué)論文范文:不同劑量阿托伐他汀對肺心病患者big�睧T及hs�睠RP及PAP水平的影響

【摘要】 目的 對肺心病并高脂血癥患者應(yīng)用不同劑量阿托伐他汀治療，觀察其調(diào)脂的同時(shí)對大內(nèi)皮素(big�睧T)及超敏C�卜磻�(yīng)蛋白(hs�睠RP)的影響，及肺動(dòng)脈壓力(PAP)改變情況。方法 將在我院就診的肺心病高脂血癥患者100例，隨機(jī)分為2組，即A組(阿托伐他汀10 mg，每晚1次)、B組(阿托伐他汀20 mg，每晚1次)。2組之間匹配非處理因素，比較2組治療24周后血脂水平，big�睧T及Hs�睠RP、PAP變化情況。結(jié)果 2組在治療24周后血脂及內(nèi)皮功能、肺動(dòng)脈壓力均有改善，血清hs�睠RP水平均有降低(P<0.05)， B組24周后big�睧T水平及hs�睠RP水平明顯低于A組(P<0.05)。PAP改善B組較A組明顯(P<0.05)。2組之間不良反應(yīng)率間差異有統(tǒng)計(jì)學(xué)意義(P<0.01)。結(jié)論 他汀類藥物在調(diào)脂的同時(shí)具有非調(diào)脂依賴性心臟保護(hù)作用，可改善血管內(nèi)皮功能、抑制慢性炎癥反應(yīng)，降低肺動(dòng)脈壓力、改善心功能，并隨劑量的增加其作用增加。

【關(guān)鍵詞】 肺心病;高脂血癥;內(nèi)皮縮血管肽類;超敏C�卜磻�(yīng)蛋白;阿托伐他汀

Effects of different doses of atorvastatin on serum lipids, big�睧T, hs�睠RP and PAP in hyperlipidemia patients with chronic cor pulmonale ZHU Yanhui, WANG Xizhu, SONG Qiaofeng, et al.Department of Cardiology, People’s Hospital of Tangshan city,Hebei,Tangshan 063000,China

【Abstract】 Objective To investigate the safety and therapeutic effect of different doses of atorvastatin on lipid�瞝owering,endothelial function,high�瞫ensitivity C�瞨eactive protein(hs�睠RP)and pulmonary artery pressure(PAP)in hyperlipidemia patients with chronic cor pulmonale.Methods 100 hyperlipidemia patients with chronic cor pulmonale were randomly divided into two groups.The patients in disorder lipidemia group were given atorvastatin 10mg qd or 20 mg qd for 24 weeks. The levels of TC, TG, LDL�睠, HDL�睠, big�睧T and hs�睠RP, PAP were determined in disorder lipidemia groups 24 hours after pretreatment or treatment.Results TC and LDL�睠 were decreased significantly(P<0.05)in both groups after 24 weeks, but the decrease in atorvastatin 20mg qd group was more obvious. Big�睧T in atorvastatin 20mg qd group was reduced from (0.69±0.26 )pmol/L before treatment to (0.43±0.07) pmol/L after 24�瞱eek treatment,which also was significantly lower than that of atorvastatin 10mg qd group(0.51±0.08)pmol/L (P<0.05). hs�睠RP in atorvastatin 20mg qd group was decreased from(7.1±2.1)mg/L before treatment to(3.8±0.4)mg/L after 24�瞱eek treatment, which was significantly lower than that of atorvastatin 10mg qd group(4.4±0.6) mg/L(P<0.05). PAP in atorvastatin 20mg qd group was reduced from(54±18)mmHg before treatment to(30±7)mmHg after 24�瞱eek treatment, which was significantly lower than that of atorvastatin 10mg qd group(42±8)mmHg(P<0.05).Conclusion The atorvanstain can reduce obviously blood lipid,hs�睠RP and PAP,and can improve endothelial function. The administration of atorvanstain 20mg qd is safe, which is effective in controlling blood lipid,decreasing hs�睠RP,PAP and improving endothelial function醫(yī).學(xué)全.在.線網(wǎng)站quanxiangyun.cn.

【Key words】 pulmonary heart disease; hyperlipidemia; endothelins;high�瞫ensitivity C�瞨eactive protein;atorvastatin

[1] [2] [3] [4] [5] 下一頁